Remuneration in Danish Large Cap Companies Benchmarking Executive Management and Board Remuneration
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Insights from Danish Companies Hanne Shapiro Futures and Finansforbundet Table of Contents
SUMMARY THE FINANCIAL LABOUR MARKET OF THE FUTURE INSIGHTS FROM DANISH COMPANIES HANNE SHAPIRO FUTURES AND FINANSFORBUNDET TABLE OF CONTENTS INSIGHTS FROM DANISH COMPANIES ..................................................4 TOPIC 1 A CHANGING SECTOR –NEW PARTNERSHIPS ................................................................................................6 TOPIC 2 AUGMENTATION VS. AUTOMATION ..........................................................8 TOPIC 3 CHANGES IN HOW WE WORK ..........................................................................10 TOPIC 4 NEW ROLES FOR HR AND MANAGERS .................................................12 TOPIC 5 DEVELOPMENTS IN SKILLS AND NEW JOB PROFILES ......................................................................................................14 TOPIC 6 NEW WAYS OF LEARNING ....................................................................................18 BEHIND THE RESULTS: INTERVIEWS WITH SELECT COMPANIES Hanne Shapiro Futures has conducted interviews with the following companies: Bankdata, Danske Bank, Jyske Bank, Nykredit, SimCorp, Sparekassen Kronjylland, Spar Nord Bank and Tryg Forsikring. The cases were selected based on a desire to reflect the diversification characteristic to the financial sector. However, the cases do not fully depict the diversity that characterises the financial sector and its value chain. For most of the companies, several interviews were conducted with both managers and employees. Josefine Boel Rasmussen from Finansforbundet participated -
Full Portfolio Holdings
Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd. -
Xtrackers Etfs
Xtrackers*/** Société d’investissement à capital variable R.C.S. Luxembourg N° B-119.899 Unaudited Semi-Annual Report For the period from 1 January 2018 to 30 June 2018 No subscription can be accepted on the basis of the financial reports. Subscriptions are only valid if they are made on the basis of the latest published prospectus of Xtrackers accompanied by the latest annual report and the most recent semi-annual report, if published thereafter. * Effective 16 February 2018, db x-trackers changed name to Xtrackers. **This includes synthetic ETFs. Xtrackers** Table of contents Page Organisation 4 Information for Hong Kong Residents 6 Statistics 7 Statement of Net Assets as at 30 June 2018 28 Statement of Investments as at 30 June 2018 50 Xtrackers MSCI WORLD SWAP UCITS ETF* 50 Xtrackers MSCI EUROPE UCITS ETF 56 Xtrackers MSCI JAPAN UCITS ETF 68 Xtrackers MSCI USA SWAP UCITS ETF* 75 Xtrackers EURO STOXX 50 UCITS ETF 80 Xtrackers DAX UCITS ETF 82 Xtrackers FTSE MIB UCITS ETF 83 Xtrackers SWITZERLAND UCITS ETF 85 Xtrackers FTSE 100 INCOME UCITS ETF 86 Xtrackers FTSE 250 UCITS ETF 89 Xtrackers FTSE ALL-SHARE UCITS ETF 96 Xtrackers MSCI EMERGING MARKETS SWAP UCITS ETF* 111 Xtrackers MSCI EM ASIA SWAP UCITS ETF* 115 Xtrackers MSCI EM LATIN AMERICA SWAP UCITS ETF* 117 Xtrackers MSCI EM EUROPE, MIDDLE EAST & AFRICA SWAP UCITS ETF* 118 Xtrackers MSCI TAIWAN UCITS ETF 120 Xtrackers MSCI BRAZIL UCITS ETF 123 Xtrackers NIFTY 50 SWAP UCITS ETF* 125 Xtrackers MSCI KOREA UCITS ETF 127 Xtrackers FTSE CHINA 50 UCITS ETF 130 Xtrackers EURO STOXX QUALITY -
The Confusions in Nordic ESG Ratings
Rating Objectivity: The Confusions in Nordic ESG Ratings ESG Ratings Subjectivity and its Consequences MASTER THESIS WITHIN: Business Administration NUMBER OF CREDITS: 30 ECTS PROGRAM OF STUDY: Civilekonom AUTHOR: John Rydholm & Samuel Schultzberg Bagge TUTOR: Fredrik Hansen & Toni Duras JÖNKÖPING May 2020 Master Thesis within Business Administration Title: Rating Objectivity: The Confusions in Nordic ESG Ratings - ESG Ratings Subjectivity and its Consequences Authors: John Rydholm, Samuel Schultzberg Bagge Tutors: Fredrik Hansen, Toni Duras Date: May 2020 Key terms: ESG, CSR, Ratings, Rating agencies, MSCI, Thomson Reuters, Sustainalytics, RobecoSAM Abstract: Environmental, Social and Governance measurements have significantly increased in usage due to growing concerns for environmental and sustainability problems in today’s world. However, with no commonly agreed-upon criteria for ESG ratings, the scoring measure creates confusion both at the investor and company level. Besides, ESG agencies have different processes and parameters for measuring ESG compliance, which contributes to the problem. The study examines four ESG rating agencies’ rating models and ESG scores to get a better understanding of deviations in ESG scores among Nordic companies. By also studying the correlation amongst ESG scores and market capitalizations in firms, the paper hopes to shed light on if any relationships exist between them. Our results show that the four major ESG raters in the study showed a weak to a non-significant correlation against each other. The maximum correlation found was 0.419 between Thomson Reuters and MSCI. RobecoSAM and MSCI showed the lowest significant correlation at 0.291. Sustainalytics was detected not to show any significant correlation with the other raters. -
Genmab Announces Data to Be Presented at 2017 ASCO Annual Meeting
Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting Media Release 8 abstracts on Genmab programs scheduled for presentation at ASCO Two daratumumab oral presentations and five daratumumab poster presentations Copenhagen, Denmark; April 20, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6. These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO website with the full abstracts scheduled to be published on May 17, 2017. “We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO conference,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. List of abstracts: Daratumumab: Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or -
Honours Programme, Industrial Track Msc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering
Honours Programme, Industrial Track MSc Chemical and Biochemical Engineering Honours Programme in Chemical and Biochemical Engineering In September 2009 DTU established honours programmes within the context of the regular MSc programmes (see:www.dtu.dk/ english). The programmes are open to highly qualified internation- al and Danish students. You can choose to focus your Honours Programme in Chemical and Biochemical Engineering on industrial research and development by following a special Industrial Track. Industrial Track The superb industrial contacts and the high international standing amongst the faculty of the Department have made it possible to form an industrial track within the Honours Programme. The philosophy is to enable the very best and most motivated stu- dents to gain from high-level, world-class industrial contacts in major Danish enterprises with operations all over the world. In this way we work to open new and exciting career prospects for the students within industrial research, innovation, process design, operation and management. The programme is coordinated with leading international Danish companies. Presently FLSmidth, Lundbeck, Novozymes, Haldor- Topsøe, and Hempel support the programme. Admission to Indus- trial Track is subject to acceptance by a partner company. 2 DTU Special features The Technical University of Denmark (DTU) is Scandinavia’s leading The honours programme, Industrial Track has some special features technical university and one of the top technical universities in Europe. over and above the normal MSc programme. These are: It has outstanding facilities for education and research in a large, open campus just north of Copenhagen. Masters courses are taught in Eng- Mentoring lish, in an innovative and open-minded learning environment. -
Ifu Project Portfolio 2018 2 | Ifu Project Portfolio 2018
IFU PROJECT PORTFOLIO 2018 2 | IFU PROJECT PORTFOLIO 2018 PROJECT Portfolio INDEPENDENT AUDitors’ report ON IFU PROJECT Portfolio 2018 Up to the end of 2018, IFU and IFU managed funds had co-financed To the Executive Board of IFU standards, applicable requirements in Danish law and other regulations. a total of 1,286 projects in 101 countries. Of these, 203 are ongoing As agreed, we have examined the IFU Project Portfolio 2018. The IFU We complied with independence requirements and other ethical stand- investments, while IFU has exited 1,083 projects. The distribution of Project Portfolio 2018 has been listed and presented in accordance with ards under FSR - Danish Auditors’ Code of Ethics for Professional all projects by region is illustrated in the figure below. the methodology and definitions described in “Note to IFU’s project Accountants, which rely on general principles regarding integrity, ob- portfolio – definitions (only in English)”. jectivity, professional competence and due care, confidentiality and professional conduct. TotAL NUMBER OF projects DistriButeD BY REGION We are to conclude on IFU Project Portfolio 2018 to ascertain whether the data and information are correctly reflected in accordance with the As part of our examinations, we performed the below procedures: methodology and definitions reflected in “Note to IFU project portfolio • A sample check of whether IFU’s recordings of the individual share Africa 278 –definitions”. The IFU Project Portfolio 2018 means IFU’s involvement capital investments/project loans, total disbursed and expected total Asia 422 in active and finalised projects, as presented by the Executive Board and investment are reconciled in accordance with the contractual frame- Europe 445 in accordance with the principles and definitions reflected in “Note to work and information provided. -
Genmab's 2020 Capital Markets
WELCOME Genmab’s 2020 Capital Markets Day November 13, 2020 Webcast Live from Utrecht and Princeton Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. -
Second Pre-Clinical Milestone Met in Lundbeck Collaboration - €1 Million Milestone Payment to Genmab
GENMAB REACHES SECOND MILESTONE IN LUNDBECK COLLABORATION - Second pre-clinical milestone met in Lundbeck collaboration - €1 million milestone payment to Genmab Copenhagen, Denmark; February 10, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS). The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million). Lundbeck fully funds the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties. “We are very pleased to have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration. This partnership is progressing well, with this second milestone coming shortly after we achieved the first preclinical milestone in December last year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. -
Annual Report 2020
S I MCOR P ANNUAL REPORT 2020 SimCorp A/S • Weidekampsgade 16 • 2300 Copenhagen S • Denmark • Company reg. no: 15505281 • www.simcorp.com SIMCORP ANNUAL REPORT 2020 | 2 A leading provider of fully integrated front-to-back, multi-asset, investment management solutions to the world’s largest institutional investment management companies Empowering unmatched operational efficiency and investment enablement MANAGEMENT REPORT CONSOLIDATED FINANCIAL STATEMENTS FINANCIAL STATEMENTS OF SIMCORP A/S 3 SimCorp at a glance 17 Financial review 2020 45 Income statement 93 Income statement 4 Business units, products and clients 24 Risk management 45 Statement of comprehensive income 93 Statement of comprehensive income 5 Business unit review 27 Corporate governance report 46 Cash flow statement 94 Cash flow statement 6 Performance and highlights 31 Shareholder information 47 Statement of financial position 95 Statement of financial position 7 CEO and Chairman letter 35 Board of Directors 48 Statement of changes in equity 96 Statement of changes in equity 9 Highlights 2016-2020 38 Executive Management Board 49 Notes 97 Notes 11 Vision and strategy 39 Group Management Committee 15 Financial targets 2021 40 Statements and signatures RELATED REPORTS Sustainability Report 2020 Remuneration Report 2020 www2.simcorp.com/SustainabilityReport2020 www2.simcorp.com/RemunerationReport2020 DISCLAIMER: SimCorp’s annual report includes certain forward-looking statements regarding the Group’s future financial situation. Such statements are based on SimCorp’s current plans, estimates, and projections. By nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and are thus not a guarantee of future performance. Accordingly, the actual performance may deviate materially from that expressed in such forward-looking statements due to a variety of factors. -
Jens Howitz (Pdf)
Ledelsesevaluering og mangfoldighed Jens M. Howitz Managing Director Russell Reynolds Associates Januar 2014 Bestyrelsesprofil under forandring 1999 2013 Hvid, mand, midaldrende Mangfoldighed: Køn, alder, erfaring Homogen profil “Old Boys Network” Overvejende international/global Relationer og kontakter Udvælgelsesproces Dansk Kompetencedrevet Specifik baggrund og indsigt: Tidligere CEO / Generalist • Finans, SCM, Branding, CSR etc. Advokat •Emerging markeder •Brancheforståelse •Uafhængighed FTSE 100 CAC40 DAX AEX OBX OMX C20 ‘09 ‘12 ‘09 ‘12 ‘09 ’12 ‘09 ‘12 ‘09 ‘13 ’09 ’13 Female 11% 21% 8% 22% 5% 10% 14% 20% 39% 38% 10% 16% NEDs ‘Foreign’ 37% 41% 28% 31% 18% 26% 48% 53% 27% 39% 24% 35% NEDs Average Age 57 60 60 61 61 62 62 61 54 52 58 57 2 Virksomheder Novo Nordisk Lundbeck A.P.Møller – Maersk GN Store Nord Danske Bank Jyske Bank Carlsberg Topdanmark Coloplast FLSmidth & Co. Novozymes DONG Energy TDC Danish Crown Pandora Coop Danmark Vestas Wind Systems DLG Tryg Danfoss DSV Grundfos William Demant Holding LEGO Chr. Hansen Holding 3 Bestyrelsesmedlemmer 2013 vs. 2003 Anciennitet i top 25 virksomheder i DK 2013 Anciennitet i top 25 virksomheder i DK 2003 100 45 90 40 80 35 70 30 60 25 Antal Medlemmer Antal Medlemmer 50 Mænd Mænd 20 40 Kvinder Kvinder 15 30 20 10 10 5 0 0 0-3 år 3-6 år 6-9 år 9-12 år 12+ 0-3 år 3-6 år 6-9 år 9-12 år 12+ 4 Bestyrelsesmedlemmers nationalitet, top 25 2013 2003 3% 13% 6% 13% Dansk Dansk Nordisk Nordisk Andet Andet 74% 91% 5 Bestyrelsessammensætning, top 25 2013 2003 Køn: 83,9 % mænd -
Breakdown of Equities, Year-End 2020
Breakdown of equities, year-end 2020 Listed Danish equities Company Number of Ownership of Voting rights Market value Company domicile equities share capital number per cent per cent DKKm ALK-Abello Denmark 830,794 7.46 4.10 2,077.0 Ambu Denmark 4,818,951 1.91 0.86 1,268.3 AP Moller - Maersk Denmark 253,690 1.27 0.90 3,358.9 Asetek Denmark 2,722,415 10.30 10.30 210.3 Bang & Olufsen Denmark 17,092,036 13.92 13.92 573.6 Bavarian Nordic Denmark 5,904,171 10.11 10.11 1,104.1 Carlsberg Denmark 1,227,664 0.84 0.27 1,197.2 Chr Hansen Denmark 1,381,570 1.06 1.06 865.4 Coloplast Denmark 1,310,347 0.61 0.35 1,218.1 Danske Bank Denmark 13,693,257 1.60 1.60 1,378.2 DFDS Denmark 1,949,162 3.32 3.32 536.4 DSV PANALPINA Denmark 2,281,956 1.00 1.00 2,327.6 Genmab Denmark 1,166,965 0.09 0.09 1,544.8 GN Store Nord Denmark 3,166,046 2.24 2.24 1,542.5 H Lundbeck Denmark 931,964 0.47 0.47 194.6 H+H International Denmark 2,107,893 11.72 11.72 278.2 Huscompagniet Denmark 615,000 3.08 3.08 76.9 INVISIO Communications Denmark 3,183,701 7.22 7.22 589.2 ISS Denmark 4,551,135 2.46 2.46 479.7 Jyske Bank 1 Denmark 455,709 0.63 0.00 106.2 Matas Denmark 1,846,027 4.82 4.82 159.5 Netcompany Group Denmark 1,660,500 3.33 3.33 1,033.7 Nilfisk Holding Denmark 1,436,062 5.29 5.29 189.0 NKT Denmark 2,637,690 6.14 6.14 715.3 Novo Nordisk Denmark 7,546,288 0.32 0.11 3,219.6 Novozymes Denmark 1,724,215 0.61 0.23 602.6 Nordic Transport Group Denmark 1,086,064 4.80 4.80 278.0 Pandora Denmark 2,153,187 2.16 2.16 1,466.3 Per Aarsleff Holding Denmark 2,064,304 10.13 6.34 636.8 Ringkjoebing